… Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted
treatment strategy is needed. … We aimed to provide an extensive validation of IPSS-M. …

Introduction Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms
characterized by peripheral blood cytopenia and increased risk of evolution into acute …

Aim: To describe the treatment landscape and associated economic burden for myelodysplastic
syndrome in Japan. Methods: We studied nationwide retrospective claims data from …

… Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies
characterized by clonal hematopoiesis and ineffective blood cell production, resulting in …

… This study shows the treatment outcomes in a real-world population of older patients with
MDS. Treatment duration and median OS after treatment discontinuation were relatively limited…

… Validation in other cohorts is still needed. Finally, and most importantly, patients with low, …
Validation of our results in other cohorts will help further define the prognostic role of …

Abstract Treatment with hypomethylating agents (HMAs) azacitidine or decitabine is the
current standard of care for high risk myelodysplastic syndromes (MDSs) but is associated with …

… in quality of life as measured by validated PRO tools. … Real-life data consistently show
how clinical outcomes fall … disease, and to the feasibility of using it in the real world (54). …

… validation cohorts with a 1:1 ratio based on an equal proportion of the IPSS-R. Patient
characteristics for the training cohort and independent validation … model was further validated in an …

… Real-world data on patients with cancer developing secondary malignancies such as
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are lacking. This study …